nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—Abacavir—acquired immunodeficiency syndrome	0.302	1	CrCtD
Cladribine—POLE3—acquired immunodeficiency syndrome	0.213	1	CbGaD
Cladribine—PNP—Didanosine—acquired immunodeficiency syndrome	0.137	0.687	CbGbCtD
Cladribine—Entecavir—Didanosine—acquired immunodeficiency syndrome	0.0392	0.187	CrCrCtD
Cladribine—Idoxuridine—Zidovudine—acquired immunodeficiency syndrome	0.0186	0.0888	CrCrCtD
Cladribine—Trifluridine—Stavudine—acquired immunodeficiency syndrome	0.0186	0.0888	CrCrCtD
Cladribine—Telbivudine—Stavudine—acquired immunodeficiency syndrome	0.0186	0.0888	CrCrCtD
Cladribine—Trifluridine—Zidovudine—acquired immunodeficiency syndrome	0.0186	0.0888	CrCrCtD
Cladribine—Telbivudine—Zidovudine—acquired immunodeficiency syndrome	0.0186	0.0888	CrCrCtD
Cladribine—Idoxuridine—Stavudine—acquired immunodeficiency syndrome	0.0186	0.0888	CrCrCtD
Cladribine—Nelarabine—Abacavir—acquired immunodeficiency syndrome	0.0172	0.0819	CrCrCtD
Cladribine—Floxuridine—Zidovudine—acquired immunodeficiency syndrome	0.017	0.0808	CrCrCtD
Cladribine—Floxuridine—Stavudine—acquired immunodeficiency syndrome	0.017	0.0808	CrCrCtD
Cladribine—DCK—Lamivudine—acquired immunodeficiency syndrome	0.0143	0.0714	CbGbCtD
Cladribine—Decitabine—Lamivudine—acquired immunodeficiency syndrome	0.00773	0.0368	CrCrCtD
Cladribine—SLC22A1—Indinavir—acquired immunodeficiency syndrome	0.00549	0.0275	CbGbCtD
Cladribine—SLC22A1—Nelfinavir—acquired immunodeficiency syndrome	0.00533	0.0267	CbGbCtD
Cladribine—SLC22A2—Zidovudine—acquired immunodeficiency syndrome	0.00532	0.0266	CbGbCtD
Cladribine—SLC22A1—Saquinavir—acquired immunodeficiency syndrome	0.00482	0.0241	CbGbCtD
Cladribine—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.00453	0.0227	CbGbCtD
Cladribine—SLC22A2—Lamivudine—acquired immunodeficiency syndrome	0.00412	0.0206	CbGbCtD
Cladribine—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0041	0.0205	CbGbCtD
Cladribine—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0041	0.0205	CbGbCtD
Cladribine—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.00393	0.0197	CbGbCtD
Cladribine—SLC22A1—Lamivudine—acquired immunodeficiency syndrome	0.00358	0.0179	CbGbCtD
Cladribine—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00304	0.0152	CbGbCtD
Cladribine—PNP—blood plasma—acquired immunodeficiency syndrome	0.00089	0.0382	CbGeAlD
Cladribine—POLE4—skin of body—acquired immunodeficiency syndrome	0.000774	0.0332	CbGeAlD
Cladribine—POLE2—blood—acquired immunodeficiency syndrome	0.000516	0.0221	CbGeAlD
Cladribine—POLE2—bone marrow—acquired immunodeficiency syndrome	0.000499	0.0214	CbGeAlD
Cladribine—POLE4—nervous system—acquired immunodeficiency syndrome	0.000479	0.0205	CbGeAlD
Cladribine—POLE2—vagina—acquired immunodeficiency syndrome	0.000478	0.0205	CbGeAlD
Cladribine—POLE4—central nervous system—acquired immunodeficiency syndrome	0.000461	0.0198	CbGeAlD
Cladribine—POLE2—lung—acquired immunodeficiency syndrome	0.000452	0.0194	CbGeAlD
Cladribine—POLE2—Floxuridine—Stavudine—acquired immunodeficiency syndrome	0.000389	0.5	CbGdCrCtD
Cladribine—POLE2—Floxuridine—Zidovudine—acquired immunodeficiency syndrome	0.000389	0.5	CbGdCrCtD
Cladribine—POLE4—brain—acquired immunodeficiency syndrome	0.000366	0.0157	CbGeAlD
Cladribine—PNP—lymphoid tissue—acquired immunodeficiency syndrome	0.000346	0.0149	CbGeAlD
Cladribine—PNP—digestive system—acquired immunodeficiency syndrome	0.000342	0.0147	CbGeAlD
Cladribine—PNP—blood—acquired immunodeficiency syndrome	0.000326	0.014	CbGeAlD
Cladribine—PNP—bone marrow—acquired immunodeficiency syndrome	0.000316	0.0135	CbGeAlD
Cladribine—POLE2—lymph node—acquired immunodeficiency syndrome	0.000309	0.0133	CbGeAlD
Cladribine—POLE3—lymphoid tissue—acquired immunodeficiency syndrome	0.000304	0.013	CbGeAlD
Cladribine—RRM2B—blood—acquired immunodeficiency syndrome	0.000303	0.013	CbGeAlD
Cladribine—POLE3—digestive system—acquired immunodeficiency syndrome	0.0003	0.0129	CbGeAlD
Cladribine—NR5A1—lymphoid tissue—acquired immunodeficiency syndrome	0.000295	0.0126	CbGeAlD
Cladribine—RRM2B—bone marrow—acquired immunodeficiency syndrome	0.000293	0.0126	CbGeAlD
Cladribine—RRM2B—spinal cord—acquired immunodeficiency syndrome	0.000292	0.0125	CbGeAlD
Cladribine—POLE3—blood—acquired immunodeficiency syndrome	0.000286	0.0123	CbGeAlD
Cladribine—PNP—lung—acquired immunodeficiency syndrome	0.000286	0.0123	CbGeAlD
Cladribine—POLA1—retina—acquired immunodeficiency syndrome	0.000281	0.0121	CbGeAlD
Cladribine—SLC28A3—digestive system—acquired immunodeficiency syndrome	0.000281	0.0121	CbGeAlD
Cladribine—RRM2B—vagina—acquired immunodeficiency syndrome	0.000281	0.012	CbGeAlD
Cladribine—POLE3—bone marrow—acquired immunodeficiency syndrome	0.000277	0.0119	CbGeAlD
Cladribine—POLE3—spinal cord—acquired immunodeficiency syndrome	0.000276	0.0118	CbGeAlD
Cladribine—RRM2B—lung—acquired immunodeficiency syndrome	0.000265	0.0114	CbGeAlD
Cladribine—POLE3—vagina—acquired immunodeficiency syndrome	0.000265	0.0114	CbGeAlD
Cladribine—PNP—nervous system—acquired immunodeficiency syndrome	0.000265	0.0114	CbGeAlD
Cladribine—SLC28A3—bone marrow—acquired immunodeficiency syndrome	0.000259	0.0111	CbGeAlD
Cladribine—PNP—central nervous system—acquired immunodeficiency syndrome	0.000255	0.0109	CbGeAlD
Cladribine—POLE3—lung—acquired immunodeficiency syndrome	0.000251	0.0108	CbGeAlD
Cladribine—RRM2B—nervous system—acquired immunodeficiency syndrome	0.000246	0.0105	CbGeAlD
Cladribine—RRM2B—central nervous system—acquired immunodeficiency syndrome	0.000237	0.0101	CbGeAlD
Cladribine—RRM2—skin of body—acquired immunodeficiency syndrome	0.000236	0.0101	CbGeAlD
Cladribine—SLC28A3—lung—acquired immunodeficiency syndrome	0.000235	0.0101	CbGeAlD
Cladribine—POLE3—nervous system—acquired immunodeficiency syndrome	0.000232	0.00996	CbGeAlD
Cladribine—POLE—lymphoid tissue—acquired immunodeficiency syndrome	0.000232	0.00995	CbGeAlD
Cladribine—POLE—digestive system—acquired immunodeficiency syndrome	0.000229	0.00983	CbGeAlD
Cladribine—NR5A1—nervous system—acquired immunodeficiency syndrome	0.000225	0.00966	CbGeAlD
Cladribine—POLE3—central nervous system—acquired immunodeficiency syndrome	0.000224	0.00959	CbGeAlD
Cladribine—RRM1—retina—acquired immunodeficiency syndrome	0.000223	0.00958	CbGeAlD
Cladribine—POLE—blood—acquired immunodeficiency syndrome	0.000218	0.00936	CbGeAlD
Cladribine—NR5A1—central nervous system—acquired immunodeficiency syndrome	0.000217	0.0093	CbGeAlD
Cladribine—POLE—bone marrow—acquired immunodeficiency syndrome	0.000211	0.00906	CbGeAlD
Cladribine—POLE—vagina—acquired immunodeficiency syndrome	0.000202	0.00868	CbGeAlD
Cladribine—PNP—brain—acquired immunodeficiency syndrome	0.000202	0.00868	CbGeAlD
Cladribine—RRM1—skin of body—acquired immunodeficiency syndrome	0.000196	0.00841	CbGeAlD
Cladribine—POLE—lung—acquired immunodeficiency syndrome	0.000191	0.00821	CbGeAlD
Cladribine—RRM2—lymphoid tissue—acquired immunodeficiency syndrome	0.000191	0.00819	CbGeAlD
Cladribine—RRM2—digestive system—acquired immunodeficiency syndrome	0.000189	0.00809	CbGeAlD
Cladribine—POLA1—blood—acquired immunodeficiency syndrome	0.000188	0.00807	CbGeAlD
Cladribine—RRM2B—brain—acquired immunodeficiency syndrome	0.000188	0.00806	CbGeAlD
Cladribine—POLA1—bone marrow—acquired immunodeficiency syndrome	0.000182	0.00781	CbGeAlD
Cladribine—RRM2B—lymph node—acquired immunodeficiency syndrome	0.000181	0.00779	CbGeAlD
Cladribine—RRM2—blood—acquired immunodeficiency syndrome	0.00018	0.00771	CbGeAlD
Cladribine—POLE3—brain—acquired immunodeficiency syndrome	0.000178	0.00762	CbGeAlD
Cladribine—POLE—nervous system—acquired immunodeficiency syndrome	0.000177	0.0076	CbGeAlD
Cladribine—POLA1—vagina—acquired immunodeficiency syndrome	0.000174	0.00748	CbGeAlD
Cladribine—RRM2—bone marrow—acquired immunodeficiency syndrome	0.000174	0.00746	CbGeAlD
Cladribine—DCK—retina—acquired immunodeficiency syndrome	0.000173	0.00744	CbGeAlD
Cladribine—NR5A1—brain—acquired immunodeficiency syndrome	0.000172	0.00738	CbGeAlD
Cladribine—POLE3—lymph node—acquired immunodeficiency syndrome	0.000172	0.00736	CbGeAlD
Cladribine—POLE—central nervous system—acquired immunodeficiency syndrome	0.000171	0.00732	CbGeAlD
Cladribine—RRM2—vagina—acquired immunodeficiency syndrome	0.000167	0.00715	CbGeAlD
Cladribine—POLA1—lung—acquired immunodeficiency syndrome	0.000165	0.00708	CbGeAlD
Cladribine—RRM1—lymphoid tissue—acquired immunodeficiency syndrome	0.000159	0.00681	CbGeAlD
Cladribine—RRM2—lung—acquired immunodeficiency syndrome	0.000158	0.00676	CbGeAlD
Cladribine—RRM1—digestive system—acquired immunodeficiency syndrome	0.000157	0.00672	CbGeAlD
Cladribine—RRM1—blood—acquired immunodeficiency syndrome	0.000149	0.00641	CbGeAlD
Cladribine—SLC22A2—digestive system—acquired immunodeficiency syndrome	0.000147	0.00631	CbGeAlD
Cladribine—RRM2—nervous system—acquired immunodeficiency syndrome	0.000146	0.00626	CbGeAlD
Cladribine—RRM1—bone marrow—acquired immunodeficiency syndrome	0.000144	0.0062	CbGeAlD
Cladribine—RRM1—spinal cord—acquired immunodeficiency syndrome	0.000144	0.00617	CbGeAlD
Cladribine—RRM2—central nervous system—acquired immunodeficiency syndrome	0.00014	0.00603	CbGeAlD
Cladribine—RRM1—vagina—acquired immunodeficiency syndrome	0.000138	0.00594	CbGeAlD
Cladribine—POLE—brain—acquired immunodeficiency syndrome	0.000135	0.00581	CbGeAlD
Cladribine—RRM1—lung—acquired immunodeficiency syndrome	0.000131	0.00562	CbGeAlD
Cladribine—POLE—lymph node—acquired immunodeficiency syndrome	0.000131	0.00561	CbGeAlD
Cladribine—DCK—lymphoid tissue—acquired immunodeficiency syndrome	0.000123	0.00529	CbGeAlD
Cladribine—DCK—digestive system—acquired immunodeficiency syndrome	0.000122	0.00522	CbGeAlD
Cladribine—RRM1—nervous system—acquired immunodeficiency syndrome	0.000121	0.0052	CbGeAlD
Cladribine—POLA1—brain—acquired immunodeficiency syndrome	0.000117	0.00501	CbGeAlD
Cladribine—RRM1—central nervous system—acquired immunodeficiency syndrome	0.000117	0.00501	CbGeAlD
Cladribine—DCK—blood—acquired immunodeficiency syndrome	0.000116	0.00498	CbGeAlD
Cladribine—POLA1—lymph node—acquired immunodeficiency syndrome	0.000113	0.00484	CbGeAlD
Cladribine—DCK—bone marrow—acquired immunodeficiency syndrome	0.000112	0.00481	CbGeAlD
Cladribine—DCK—spinal cord—acquired immunodeficiency syndrome	0.000112	0.00479	CbGeAlD
Cladribine—RRM2—brain—acquired immunodeficiency syndrome	0.000112	0.00479	CbGeAlD
Cladribine—RRM2—lymph node—acquired immunodeficiency syndrome	0.000108	0.00462	CbGeAlD
Cladribine—DCK—vagina—acquired immunodeficiency syndrome	0.000108	0.00461	CbGeAlD
Cladribine—DCK—lung—acquired immunodeficiency syndrome	0.000102	0.00436	CbGeAlD
Cladribine—SLC22A1—blood—acquired immunodeficiency syndrome	9.89e-05	0.00424	CbGeAlD
Cladribine—DCK—nervous system—acquired immunodeficiency syndrome	9.42e-05	0.00404	CbGeAlD
Cladribine—RRM1—brain—acquired immunodeficiency syndrome	9.27e-05	0.00398	CbGeAlD
Cladribine—SLC22A1—vagina—acquired immunodeficiency syndrome	9.17e-05	0.00393	CbGeAlD
Cladribine—DCK—central nervous system—acquired immunodeficiency syndrome	9.07e-05	0.00389	CbGeAlD
Cladribine—RRM1—lymph node—acquired immunodeficiency syndrome	8.95e-05	0.00384	CbGeAlD
Cladribine—SLC22A1—nervous system—acquired immunodeficiency syndrome	8.03e-05	0.00345	CbGeAlD
Cladribine—SLC22A1—central nervous system—acquired immunodeficiency syndrome	7.73e-05	0.00332	CbGeAlD
Cladribine—DCK—brain—acquired immunodeficiency syndrome	7.2e-05	0.00309	CbGeAlD
Cladribine—DCK—lymph node—acquired immunodeficiency syndrome	6.95e-05	0.00298	CbGeAlD
Cladribine—ABCG2—blood—acquired immunodeficiency syndrome	6.47e-05	0.00278	CbGeAlD
Cladribine—ABCG2—bone marrow—acquired immunodeficiency syndrome	6.26e-05	0.00269	CbGeAlD
Cladribine—ABCG2—spinal cord—acquired immunodeficiency syndrome	6.23e-05	0.00267	CbGeAlD
Cladribine—SLC22A1—brain—acquired immunodeficiency syndrome	6.14e-05	0.00263	CbGeAlD
Cladribine—ABCG2—vagina—acquired immunodeficiency syndrome	6e-05	0.00257	CbGeAlD
Cladribine—ABCG2—lung—acquired immunodeficiency syndrome	5.67e-05	0.00243	CbGeAlD
Cladribine—ABCG2—brain—acquired immunodeficiency syndrome	4.02e-05	0.00172	CbGeAlD
Cladribine—ABCG2—lymph node—acquired immunodeficiency syndrome	3.88e-05	0.00166	CbGeAlD
Cladribine—Malaise—Saquinavir—acquired immunodeficiency syndrome	3.01e-05	0.000598	CcSEcCtD
Cladribine—Somnolence—Indinavir—acquired immunodeficiency syndrome	3.01e-05	0.000598	CcSEcCtD
Cladribine—Asthenia—Stavudine—acquired immunodeficiency syndrome	3.01e-05	0.000597	CcSEcCtD
Cladribine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	3e-05	0.000596	CcSEcCtD
Cladribine—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	3e-05	0.000595	CcSEcCtD
Cladribine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	2.99e-05	0.000593	CcSEcCtD
Cladribine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	2.98e-05	0.000591	CcSEcCtD
Cladribine—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	2.97e-05	0.000591	CcSEcCtD
Cladribine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	2.97e-05	0.000591	CcSEcCtD
Cladribine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	2.97e-05	0.00059	CcSEcCtD
Cladribine—Pruritus—Stavudine—acquired immunodeficiency syndrome	2.96e-05	0.000589	CcSEcCtD
Cladribine—Asthenia—Abacavir—acquired immunodeficiency syndrome	2.96e-05	0.000588	CcSEcCtD
Cladribine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	2.96e-05	0.000588	CcSEcCtD
Cladribine—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	2.96e-05	0.000587	CcSEcCtD
Cladribine—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	2.95e-05	0.000587	CcSEcCtD
Cladribine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	2.95e-05	0.000587	CcSEcCtD
Cladribine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	2.95e-05	0.000587	CcSEcCtD
Cladribine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	2.94e-05	0.000585	CcSEcCtD
Cladribine—Anaemia—Lamivudine—acquired immunodeficiency syndrome	2.94e-05	0.000585	CcSEcCtD
Cladribine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	2.94e-05	0.000585	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	2.93e-05	0.000583	CcSEcCtD
Cladribine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	2.92e-05	0.000581	CcSEcCtD
Cladribine—Pruritus—Abacavir—acquired immunodeficiency syndrome	2.92e-05	0.00058	CcSEcCtD
Cladribine—Fatigue—Indinavir—acquired immunodeficiency syndrome	2.92e-05	0.00058	CcSEcCtD
Cladribine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	2.92e-05	0.00058	CcSEcCtD
Cladribine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	2.92e-05	0.00058	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	2.92e-05	0.000579	CcSEcCtD
Cladribine—Cough—Saquinavir—acquired immunodeficiency syndrome	2.91e-05	0.000579	CcSEcCtD
Cladribine—Pain—Indinavir—acquired immunodeficiency syndrome	2.9e-05	0.000575	CcSEcCtD
Cladribine—Constipation—Indinavir—acquired immunodeficiency syndrome	2.9e-05	0.000575	CcSEcCtD
Cladribine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	2.89e-05	0.000575	CcSEcCtD
Cladribine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	2.89e-05	0.000575	CcSEcCtD
Cladribine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	2.88e-05	0.000572	CcSEcCtD
Cladribine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	2.88e-05	0.000572	CcSEcCtD
Cladribine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	2.88e-05	0.000571	CcSEcCtD
Cladribine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	2.87e-05	0.000571	CcSEcCtD
Cladribine—Malaise—Lamivudine—acquired immunodeficiency syndrome	2.87e-05	0.00057	CcSEcCtD
Cladribine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	2.87e-05	0.000569	CcSEcCtD
Cladribine—Nausea—Didanosine—acquired immunodeficiency syndrome	2.87e-05	0.000569	CcSEcCtD
Cladribine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	2.86e-05	0.000568	CcSEcCtD
Cladribine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	2.86e-05	0.000567	CcSEcCtD
Cladribine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	2.85e-05	0.000567	CcSEcCtD
Cladribine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	2.84e-05	0.000565	CcSEcCtD
Cladribine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	2.84e-05	0.000565	CcSEcCtD
Cladribine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	2.84e-05	0.000565	CcSEcCtD
Cladribine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	2.84e-05	0.000565	CcSEcCtD
Cladribine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	2.83e-05	0.000563	CcSEcCtD
Cladribine—Oedema—Ritonavir—acquired immunodeficiency syndrome	2.83e-05	0.000562	CcSEcCtD
Cladribine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	2.82e-05	0.000561	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	2.82e-05	0.000561	CcSEcCtD
Cladribine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	2.81e-05	0.000558	CcSEcCtD
Cladribine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	2.79e-05	0.000554	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	2.79e-05	0.000554	CcSEcCtD
Cladribine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	2.78e-05	0.000552	CcSEcCtD
Cladribine—Cough—Lamivudine—acquired immunodeficiency syndrome	2.78e-05	0.000552	CcSEcCtD
Cladribine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	2.78e-05	0.000552	CcSEcCtD
Cladribine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	2.78e-05	0.000551	CcSEcCtD
Cladribine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	2.77e-05	0.000551	CcSEcCtD
Cladribine—Dizziness—Stavudine—acquired immunodeficiency syndrome	2.77e-05	0.00055	CcSEcCtD
Cladribine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	2.77e-05	0.00055	CcSEcCtD
Cladribine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	2.77e-05	0.00055	CcSEcCtD
Cladribine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	2.76e-05	0.000549	CcSEcCtD
Cladribine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	2.76e-05	0.000549	CcSEcCtD
Cladribine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	2.76e-05	0.000548	CcSEcCtD
Cladribine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	2.76e-05	0.000548	CcSEcCtD
Cladribine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	2.75e-05	0.000546	CcSEcCtD
Cladribine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	2.75e-05	0.000546	CcSEcCtD
Cladribine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	2.75e-05	0.000546	CcSEcCtD
Cladribine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	2.74e-05	0.000544	CcSEcCtD
Cladribine—Constipation—Efavirenz—acquired immunodeficiency syndrome	2.74e-05	0.000543	CcSEcCtD
Cladribine—Pain—Efavirenz—acquired immunodeficiency syndrome	2.74e-05	0.000543	CcSEcCtD
Cladribine—Rash—Nevirapine—acquired immunodeficiency syndrome	2.74e-05	0.000543	CcSEcCtD
Cladribine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	2.73e-05	0.000543	CcSEcCtD
Cladribine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	2.73e-05	0.000542	CcSEcCtD
Cladribine—Dizziness—Abacavir—acquired immunodeficiency syndrome	2.73e-05	0.000542	CcSEcCtD
Cladribine—Oedema—Saquinavir—acquired immunodeficiency syndrome	2.73e-05	0.000541	CcSEcCtD
Cladribine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	2.72e-05	0.000541	CcSEcCtD
Cladribine—Headache—Nevirapine—acquired immunodeficiency syndrome	2.72e-05	0.00054	CcSEcCtD
Cladribine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	2.71e-05	0.000539	CcSEcCtD
Cladribine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	2.71e-05	0.000539	CcSEcCtD
Cladribine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	2.71e-05	0.000539	CcSEcCtD
Cladribine—Infection—Saquinavir—acquired immunodeficiency syndrome	2.71e-05	0.000538	CcSEcCtD
Cladribine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	2.7e-05	0.000537	CcSEcCtD
Cladribine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	2.7e-05	0.000536	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	2.69e-05	0.000535	CcSEcCtD
Cladribine—Urticaria—Indinavir—acquired immunodeficiency syndrome	2.69e-05	0.000534	CcSEcCtD
Cladribine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	2.68e-05	0.000532	CcSEcCtD
Cladribine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	2.68e-05	0.000532	CcSEcCtD
Cladribine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	2.68e-05	0.000532	CcSEcCtD
Cladribine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	2.67e-05	0.000531	CcSEcCtD
Cladribine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	2.67e-05	0.000531	CcSEcCtD
Cladribine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	2.67e-05	0.00053	CcSEcCtD
Cladribine—Vomiting—Stavudine—acquired immunodeficiency syndrome	2.66e-05	0.000529	CcSEcCtD
Cladribine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	2.66e-05	0.000529	CcSEcCtD
Cladribine—Rash—Nelfinavir—acquired immunodeficiency syndrome	2.65e-05	0.000526	CcSEcCtD
Cladribine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	2.65e-05	0.000526	CcSEcCtD
Cladribine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	2.65e-05	0.000526	CcSEcCtD
Cladribine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	2.65e-05	0.000525	CcSEcCtD
Cladribine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	2.64e-05	0.000525	CcSEcCtD
Cladribine—Rash—Stavudine—acquired immunodeficiency syndrome	2.64e-05	0.000525	CcSEcCtD
Cladribine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	2.64e-05	0.000524	CcSEcCtD
Cladribine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	2.64e-05	0.000524	CcSEcCtD
Cladribine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	2.64e-05	0.000524	CcSEcCtD
Cladribine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	2.63e-05	0.000523	CcSEcCtD
Cladribine—Headache—Nelfinavir—acquired immunodeficiency syndrome	2.63e-05	0.000523	CcSEcCtD
Cladribine—Headache—Stavudine—acquired immunodeficiency syndrome	2.63e-05	0.000521	CcSEcCtD
Cladribine—Vomiting—Abacavir—acquired immunodeficiency syndrome	2.62e-05	0.000521	CcSEcCtD
Cladribine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	2.62e-05	0.000521	CcSEcCtD
Cladribine—Pain—Delavirdine—acquired immunodeficiency syndrome	2.62e-05	0.00052	CcSEcCtD
Cladribine—Constipation—Delavirdine—acquired immunodeficiency syndrome	2.62e-05	0.00052	CcSEcCtD
Cladribine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	2.62e-05	0.00052	CcSEcCtD
Cladribine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	2.61e-05	0.000519	CcSEcCtD
Cladribine—Rash—Abacavir—acquired immunodeficiency syndrome	2.6e-05	0.000517	CcSEcCtD
Cladribine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	2.6e-05	0.000516	CcSEcCtD
Cladribine—Oedema—Lamivudine—acquired immunodeficiency syndrome	2.6e-05	0.000516	CcSEcCtD
Cladribine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	2.6e-05	0.000516	CcSEcCtD
Cladribine—Headache—Abacavir—acquired immunodeficiency syndrome	2.59e-05	0.000514	CcSEcCtD
Cladribine—Infection—Lamivudine—acquired immunodeficiency syndrome	2.58e-05	0.000513	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	2.58e-05	0.000512	CcSEcCtD
Cladribine—Nausea—Nevirapine—acquired immunodeficiency syndrome	2.58e-05	0.000512	CcSEcCtD
Cladribine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	2.58e-05	0.000512	CcSEcCtD
Cladribine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	2.56e-05	0.000509	CcSEcCtD
Cladribine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	2.55e-05	0.000506	CcSEcCtD
Cladribine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	2.55e-05	0.000506	CcSEcCtD
Cladribine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	2.55e-05	0.000506	CcSEcCtD
Cladribine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	2.54e-05	0.000505	CcSEcCtD
Cladribine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	2.54e-05	0.000505	CcSEcCtD
Cladribine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	2.53e-05	0.000502	CcSEcCtD
Cladribine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	2.53e-05	0.000502	CcSEcCtD
Cladribine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	2.53e-05	0.000501	CcSEcCtD
Cladribine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	2.52e-05	0.000501	CcSEcCtD
Cladribine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	2.52e-05	0.000501	CcSEcCtD
Cladribine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	2.52e-05	0.0005	CcSEcCtD
Cladribine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	2.51e-05	0.000499	CcSEcCtD
Cladribine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	2.5e-05	0.000497	CcSEcCtD
Cladribine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	2.5e-05	0.000496	CcSEcCtD
Cladribine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	2.5e-05	0.000496	CcSEcCtD
Cladribine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	2.49e-05	0.000495	CcSEcCtD
Cladribine—Nausea—Stavudine—acquired immunodeficiency syndrome	2.49e-05	0.000494	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	2.48e-05	0.000493	CcSEcCtD
Cladribine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	2.48e-05	0.000492	CcSEcCtD
Cladribine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	2.46e-05	0.000489	CcSEcCtD
Cladribine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	2.46e-05	0.000489	CcSEcCtD
Cladribine—Nausea—Abacavir—acquired immunodeficiency syndrome	2.45e-05	0.000487	CcSEcCtD
Cladribine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	2.45e-05	0.000486	CcSEcCtD
Cladribine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	2.44e-05	0.000485	CcSEcCtD
Cladribine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	2.44e-05	0.000485	CcSEcCtD
Cladribine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	2.43e-05	0.000483	CcSEcCtD
Cladribine—Asthenia—Indinavir—acquired immunodeficiency syndrome	2.43e-05	0.000483	CcSEcCtD
Cladribine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	2.43e-05	0.000483	CcSEcCtD
Cladribine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	2.43e-05	0.000482	CcSEcCtD
Cladribine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	2.42e-05	0.000481	CcSEcCtD
Cladribine—Pain—Ritonavir—acquired immunodeficiency syndrome	2.42e-05	0.000481	CcSEcCtD
Cladribine—Constipation—Ritonavir—acquired immunodeficiency syndrome	2.42e-05	0.000481	CcSEcCtD
Cladribine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	2.42e-05	0.000481	CcSEcCtD
Cladribine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	2.42e-05	0.000481	CcSEcCtD
Cladribine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	2.41e-05	0.000478	CcSEcCtD
Cladribine—Pruritus—Indinavir—acquired immunodeficiency syndrome	2.4e-05	0.000476	CcSEcCtD
Cladribine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	2.37e-05	0.00047	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	2.37e-05	0.00047	CcSEcCtD
Cladribine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	2.36e-05	0.000468	CcSEcCtD
Cladribine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	2.35e-05	0.000467	CcSEcCtD
Cladribine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	2.35e-05	0.000467	CcSEcCtD
Cladribine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	2.35e-05	0.000467	CcSEcCtD
Cladribine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	2.33e-05	0.000464	CcSEcCtD
Cladribine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	2.33e-05	0.000463	CcSEcCtD
Cladribine—Pain—Saquinavir—acquired immunodeficiency syndrome	2.33e-05	0.000463	CcSEcCtD
Cladribine—Constipation—Saquinavir—acquired immunodeficiency syndrome	2.33e-05	0.000463	CcSEcCtD
Cladribine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	2.32e-05	0.00046	CcSEcCtD
Cladribine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	2.32e-05	0.00046	CcSEcCtD
Cladribine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	2.32e-05	0.00046	CcSEcCtD
Cladribine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	2.32e-05	0.00046	CcSEcCtD
Cladribine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	2.31e-05	0.000459	CcSEcCtD
Cladribine—Rash—Zidovudine—acquired immunodeficiency syndrome	2.3e-05	0.000456	CcSEcCtD
Cladribine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	2.3e-05	0.000456	CcSEcCtD
Cladribine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	2.29e-05	0.000456	CcSEcCtD
Cladribine—Headache—Zidovudine—acquired immunodeficiency syndrome	2.28e-05	0.000453	CcSEcCtD
Cladribine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	2.26e-05	0.00045	CcSEcCtD
Cladribine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	2.26e-05	0.000449	CcSEcCtD
Cladribine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	2.26e-05	0.000448	CcSEcCtD
Cladribine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	2.25e-05	0.000447	CcSEcCtD
Cladribine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	2.25e-05	0.000446	CcSEcCtD
Cladribine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	2.24e-05	0.000446	CcSEcCtD
Cladribine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	2.24e-05	0.000445	CcSEcCtD
Cladribine—Dizziness—Indinavir—acquired immunodeficiency syndrome	2.24e-05	0.000445	CcSEcCtD
Cladribine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	2.24e-05	0.000445	CcSEcCtD
Cladribine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	2.24e-05	0.000445	CcSEcCtD
Cladribine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	2.23e-05	0.000443	CcSEcCtD
Cladribine—Pain—Lamivudine—acquired immunodeficiency syndrome	2.22e-05	0.000442	CcSEcCtD
Cladribine—Constipation—Lamivudine—acquired immunodeficiency syndrome	2.22e-05	0.000442	CcSEcCtD
Cladribine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	2.2e-05	0.000436	CcSEcCtD
Cladribine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	2.19e-05	0.000435	CcSEcCtD
Cladribine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	2.17e-05	0.00043	CcSEcCtD
Cladribine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	2.17e-05	0.00043	CcSEcCtD
Cladribine—Nausea—Zidovudine—acquired immunodeficiency syndrome	2.16e-05	0.00043	CcSEcCtD
Cladribine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	2.15e-05	0.000428	CcSEcCtD
Cladribine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	2.15e-05	0.000428	CcSEcCtD
Cladribine—Vomiting—Indinavir—acquired immunodeficiency syndrome	2.15e-05	0.000428	CcSEcCtD
Cladribine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	2.14e-05	0.000425	CcSEcCtD
Cladribine—Rash—Indinavir—acquired immunodeficiency syndrome	2.14e-05	0.000424	CcSEcCtD
Cladribine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	2.13e-05	0.000424	CcSEcCtD
Cladribine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	2.13e-05	0.000422	CcSEcCtD
Cladribine—Headache—Indinavir—acquired immunodeficiency syndrome	2.12e-05	0.000421	CcSEcCtD
Cladribine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	2.12e-05	0.00042	CcSEcCtD
Cladribine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	2.09e-05	0.000416	CcSEcCtD
Cladribine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	2.09e-05	0.000414	CcSEcCtD
Cladribine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	2.07e-05	0.00041	CcSEcCtD
Cladribine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	2.06e-05	0.000408	CcSEcCtD
Cladribine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	2.06e-05	0.000408	CcSEcCtD
Cladribine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	2.03e-05	0.000404	CcSEcCtD
Cladribine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	2.03e-05	0.000403	CcSEcCtD
Cladribine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	2.02e-05	0.000402	CcSEcCtD
Cladribine—Rash—Efavirenz—acquired immunodeficiency syndrome	2.02e-05	0.000401	CcSEcCtD
Cladribine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	2.02e-05	0.0004	CcSEcCtD
Cladribine—Nausea—Indinavir—acquired immunodeficiency syndrome	2.01e-05	0.0004	CcSEcCtD
Cladribine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	2.01e-05	0.000399	CcSEcCtD
Cladribine—Headache—Efavirenz—acquired immunodeficiency syndrome	2e-05	0.000398	CcSEcCtD
Cladribine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	2e-05	0.000398	CcSEcCtD
Cladribine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	1.96e-05	0.000388	CcSEcCtD
Cladribine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	1.95e-05	0.000387	CcSEcCtD
Cladribine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	1.94e-05	0.000385	CcSEcCtD
Cladribine—Rash—Delavirdine—acquired immunodeficiency syndrome	1.93e-05	0.000383	CcSEcCtD
Cladribine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	1.93e-05	0.000383	CcSEcCtD
Cladribine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	1.93e-05	0.000383	CcSEcCtD
Cladribine—Headache—Delavirdine—acquired immunodeficiency syndrome	1.92e-05	0.000381	CcSEcCtD
Cladribine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	1.92e-05	0.00038	CcSEcCtD
Cladribine—Nausea—Efavirenz—acquired immunodeficiency syndrome	1.9e-05	0.000377	CcSEcCtD
Cladribine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	1.87e-05	0.000372	CcSEcCtD
Cladribine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	1.87e-05	0.00037	CcSEcCtD
Cladribine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	1.86e-05	0.00037	CcSEcCtD
Cladribine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	1.84e-05	0.000365	CcSEcCtD
Cladribine—Nausea—Delavirdine—acquired immunodeficiency syndrome	1.82e-05	0.000361	CcSEcCtD
Cladribine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	1.8e-05	0.000358	CcSEcCtD
Cladribine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	1.8e-05	0.000358	CcSEcCtD
Cladribine—Rash—Ritonavir—acquired immunodeficiency syndrome	1.79e-05	0.000355	CcSEcCtD
Cladribine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	1.78e-05	0.000354	CcSEcCtD
Cladribine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	1.78e-05	0.000353	CcSEcCtD
Cladribine—Headache—Ritonavir—acquired immunodeficiency syndrome	1.77e-05	0.000352	CcSEcCtD
Cladribine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	1.73e-05	0.000344	CcSEcCtD
Cladribine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	1.72e-05	0.000341	CcSEcCtD
Cladribine—Rash—Saquinavir—acquired immunodeficiency syndrome	1.72e-05	0.000341	CcSEcCtD
Cladribine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	1.72e-05	0.000341	CcSEcCtD
Cladribine—Headache—Saquinavir—acquired immunodeficiency syndrome	1.71e-05	0.000339	CcSEcCtD
Cladribine—Nausea—Ritonavir—acquired immunodeficiency syndrome	1.68e-05	0.000334	CcSEcCtD
Cladribine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	1.65e-05	0.000328	CcSEcCtD
Cladribine—Rash—Lamivudine—acquired immunodeficiency syndrome	1.64e-05	0.000326	CcSEcCtD
Cladribine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	1.64e-05	0.000325	CcSEcCtD
Cladribine—Headache—Lamivudine—acquired immunodeficiency syndrome	1.63e-05	0.000323	CcSEcCtD
Cladribine—Nausea—Saquinavir—acquired immunodeficiency syndrome	1.62e-05	0.000321	CcSEcCtD
Cladribine—Nausea—Lamivudine—acquired immunodeficiency syndrome	1.54e-05	0.000307	CcSEcCtD
